Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASC47 + semaglutide in obesity
NCT06972992Phase 1Completed
- Sponsor
- Ascletis Pharma Inc.
- Start
- Apr 2025
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ASC47 in obesity (6 cohorts), sponsored by Ascletis Pharma Inc. Primary endpoint: Adverse Events up to 71 days. Started Apr 2025; status: completed.
02
Drugs
ASC47
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06972992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06972992.